Skip to main content
Retour
SYRE logo

Spyre Therapeutics, Inc.

Qualité des données : 100%
SYRE
NASDAQ Healthcare Biotechnology
42,76 €
▲ 1,51 € (3,66%)
Cap. Boursière : 2,58B
Fourchette du Jour
41,73 € 44,08 €
Fourchette 52 Semaines
10,91 € 45,76 €
Volume
727 593
Moyenne 50J / 200J
37,13 € / 24,94 €
Clôture Précédente
41,25 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (626 pairs)

Métrique Action Médiane du Secteur
P/E -16,6 0,4
P/B 3,6 2,9
ROE % -25,2 3,7
Net Margin % 3,8
Rev Growth 5Y % 10,0
D/E 0,0 0,2

Points Clés

Debt/Equity of 0,00 — conservative balance sheet
Negative free cash flow of -169,25M

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-25,17%
ROIC-21,97%
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
0,00
Current Ratio13,25
Interest Coverage0,00

Valorisation

P/E Ratio
-16,64
P/B Ratio3,61
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0,0 Net Income (TTM) -155,20M
ROE -25,17% ROA -19,95%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -169,25M
ROIC -21,97% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,00 Current Ratio 13,25
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio -16,64 P/B Ratio 3,61
P/S Ratio N/A PEG Ratio 1,94
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 2,58B Enterprise Value 2,50B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0,0 0,0 886 000,0 2,33M 18,74M
Net Income -155,20M -208,02M -338,79M -83,82M -65,80M
EPS (Diluted) -1,98 -3,18 -46,15 -24,86 -25,02
Gross Profit -171,65M 0,0 886 000,0 2,33M 18,74M
Operating Income -209,56M -208,57M -242,30M -84,78M -65,65M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 777,78M 608,48M 341,86M 71,14M 109,93M
Total Liabilities 62,55M 90,68M 157,84M 20,84M 25,99M
Shareholders' Equity 715,24M 517,80M 184,02M 50,31M 83,94M
Total Debt 0,0 0,0 0,0 4,63M 5,06M
Cash & Equivalents 85,72M 89,42M 188,89M 34,86M 15,14M
Current Assets 777,78M 608,47M 341,53M 62,26M 98,89M
Current Liabilities 58,69M 54,06M 31,98M 14,66M 20,14M